摘要
缓激肽是血浆激肽释放酶一激肽系统的基本组成部分，具有缓激肽B1和缓激肽B2两种受体，其中缓激肽B2受体在糖尿病肾病的发生、发展中起着重要作用。动物实验也证实相关的药物具有减轻糖尿病肾病的作用，为糖尿病肾病的临床治疗提供了新的思路。
Bradykinin is an essential component of kallikrein kinin system, which have two receptors： bradykinin B1 receptor and bradykinin B2 receptor. The latter receptor plays an important role in diabetic nephropathy. Animal studies revealed that the corresponding drug therapy could reduce diabetic nephropathy. Therefore, this therapy might offer a new insight to the treatment of patients with diabetic nephropathy in the future.
出处
《国际内分泌代谢杂志》
2007年第1期37-39,共3页
International Journal of Endocrinology and Metabolism
关键词
糖尿病肾病
缓激肽
缓激肽B2受体
Diabetic nephropathy
Bradykinin
Bradykinin B2 receptors
